trending Market Intelligence /marketintelligence/en/news-insights/trending/OFcDf7kWGRKQLGZdQGSXUw2 content esgSubNav
In This List

Trillium Therapeutics cuts 40% of staff to focus on developing cancer treatment

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Trillium Therapeutics cuts 40% of staff to focus on developing cancer treatment

Trillium Therapeutics Inc. is cutting 17 jobs as part of a restructuring to focus its resources on the development of cancer treatments.

According to the company's Oct. 22 press release, the 40% reduction in staff is effective immediately, with 26 active employees remaining. The Mississauga, Ontario-based biotechnology company is looking for a partner for further development of its STING agonist program — a treatment that enhances the immune system to fight cancer tumors.

The company also plans to cut expenses through discontinuing its discovery research activities and through operational efficiencies.